• Jazz Pharmaceuticals swung to a third-quarter 2026 net loss of $483.4 million, including $754 million in Actio-related acquired IPR&D expense.
• Total revenues rose 10% year over year to $1.24 billion.
• Ziihera received FDA approval and launched for first-line treatment of adults with HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma.
• Full-year 2026 total revenues guidance increased to $4.78 billion–$4.85 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF86442) on November 02, 2026, and is solely responsible for the information contained therein.